A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IIa Clinical Trial to Evaluate the Safety and Explore the Efficacy of J2H-1702 for Non-alcoholic Steatohepatitis
Latest Information Update: 26 Feb 2025
At a glance
- Drugs J2H-1702 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors J2H Biotech
- 20 Feb 2025 Planned End Date changed from 1 Jan 2025 to 30 Oct 2025.
- 20 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 15 Apr 2025.
- 11 Mar 2024 New trial record